With Marie Skłodowska-Curie to new young researchers
TIPAT is an innovative training network for 15 early stage researchers (ESRs)/doctoral candidates. It is part of the Marie Skłodowska-Curie International Training Network (ITN) of the European Commission.
The ESRs use knowledge about the interactions between drugs, pathogens and the immune response to develop new, individualised treatments. A unique interdisciplinary team of academic experts, hospitals, start-ups and pharmaceutical companies leads this training programme. In addition to exciting science, the programme also includes training on regulatory and entrepreneurial aspects.
Ultimately, the TIPAT programme will broaden the career prospects of the participating ESRs and create a lasting educational network. Furthermore, the aim of the scientific innovations is to enable personalised antibiotic treatments to address current and future challenges of antimicrobial resistance.
‘The approach of not only working across national borders, but also bringing together science, industry and business has great potential. Starting with this in the training of young researchers is forward-looking.’
Publications
Here is an overview on publications linked to the project.
- Insights into interspecies protein binding variability using clindamycin as an example.
Ahmed H, Böhmdorfer M, Jäger W, Zeitlinger M.
J Antimicrob Chemother. 2024 Nov 18:dkae412. doi: 10.1093/jac/dkae412.
PMID: 39556193 - Interspecies variability in protein binding of antibiotics basis for translational PK/PD studies-a case study using cefazolin.
Ahmed H, Böhmdorfer M, Eberl S, Jäger W, Zeitlinger M.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0164723. doi: 10.1128/aac.01647-23. Epub 2024 Feb 20.
PMID: 38376186 - Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences.
Ahmed H, Bergmann F, Zeitlinger M.
Antibiotics (Basel). 2022 Jul 8;11(7):923. doi: 10.3390/antibiotics11070923.
PMID: 35884177 Free PMC article. Review. - Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.
Sanz Codina M, Zeitlinger M.
Clin Pharmacokinet. 2022 May;61(5):593-617. doi: 10.1007/s40262-021-01102-1. Epub 2022 Feb 25.
PMID: 35218003 Free PMC article. Review. - Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers.
Sanz-Codina M, van Os W, Pham AD, Jorda A, Wölf-Duchek M, Bergmann F, Lackner E, Lier C, van Hasselt JGC, Minichmayr IK, Dorn C, Zeitlinger M, Al Jalali V.
J Antimicrob Chemother. 2024 Dec 2;79(12):3281-3288. doi: 10.1093/jac/dkae359.
PMID: 39373642 - Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections.
van Os W, Nussbaumer-Pröll A, Pham AD, Wijnant GJ, Ngougni Pokem P, Van Bambeke F, van Hasselt JGC, Zeitlinger M.
J Antimicrob Chemother. 2024 Oct 1;79(10):2484-2492. doi: 10.1093/jac/dkae243.
PMID: 39030832 - Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin.
van Os W, Pham AD, Eberl S, Minichmayr IK, van Hasselt JGC, Zeitlinger M.
Int J Antimicrob Agents. 2024 May;63(5):107148. doi: 10.1016/j.ijantimicag.2024.107148. Epub 2024 Mar 19.
PMID: 38508535 - Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
van Os W, Zeitlinger M.
J Antimicrob Chemother. 2024 Feb 1;79(2):443-446. doi: 10.1093/jac/dkad401.PMID: 38174805 - Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination.
Sanz-Codina M, Wicha SG, Wulkersdorfer B, Al Jalali V, Van Os W, Vossen MG, Bauer M, Lackner E, Dorn C, Zeitlinger M.
J Antimicrob Chemother. 2023 Feb 1;78(2):380-388. doi: 10.1093/jac/dkac400.
PMID: 36433819